Ceftriaxone Market Size Worth USD 2.2 billion by 2031, Expanding at a CAGR of 2.9% | Exclusive Report by Transparency Market Research
August 18, 2023 08:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global ceftriaxone market is projected to flourish at a CAGR of 2.9% from 2022 to 2031....
ContraFect to Present at Cantor Antibiotics Summit
January 11, 2018 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Jan. 11, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at the 2nd Annual Superdrugs and Superbugs USA Conference
November 10, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Nov. 10, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect to Present New Data on CF-301 at ID Week 2017
September 29, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Sept. 29, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect to Present at The MicroCap Conference
September 28, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Sept. 28, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Announces Second Quarter 2017 Financial Results
August 09, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - August 09, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia
May 25, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - May 25, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Awarded $2.1 Million PRMRP Grant to Support Development of CF-301
November 17, 2016 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - November 17, 2016) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Reports Third Quarter 2016 Financial Results and Provides Business Update
November 09, 2016 16:30 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - November 09, 2016) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...
OK to Limit Pre-Dental Procedure Antibiotics to High Risk Heart Patients
June 11, 2012 16:00 ET
|
American Heart Association
Study Highlights:
The incidence of infective may not have increased after the American Heart Association changed its recommendations on the use of antibiotics before invasive dental...